WASHINGTON DC, KOMPAS.com – Moderna is developing a single vaccine that combines doses booster against Covid-19 with its experimental flu vaccine.
The company added that the vaccine it is working on is intended to fight respiratory viruses (RSV) and other respiratory diseases as an annual dose.
The statement was delivered by the pharmaceutical and biotechnology company from the United States (US) on Thursday (9/9/2021) as reported by Reuters.
Also read: Moderna: Contaminated Covid-19 Vaccine in Japan Contain Steel Particles
In his presentation to investors, Moderna’s Chief Executive Officer (CEO) Stephane Bancel said that this is a great opportunity.
“We believe this is a huge opportunity that lies ahead of us, if we can bring it to market yearly pan-respiratory high efficacy,” said Bancel.
Get information, inspiration and insight from email you.
“We believe Moderna can be the first to market this important new opportunity,” continued Bancel.
Currently, the company is conducting clinical trials for the RSV vaccine in older adults.
Also read: Japan Finds Black Particles In Moderna Covid-19 Vaccine Bottles
Reuters reports, a number of healthcare analysts and investors estimate that Moderna and Pfizer-BioNTech will reap billions of dollars from injections. booster Covid-19.
On Thursday, Moderna shares were up 6.2 percent.
Moderna also already has several future influenza vaccines under development.
We can end the Covid-19 pandemic if we unite against it. History has proven that vaccines have saved the world from pandemics several times.
Vaccines are one of the most valuable discoveries in the world of science. Don’t hesitate and don’t be afraid to get vaccinated. Check vaccination updates.
Let’s help health workers and our neighbors who are affected by Covid-19. Click here to donate via Kitabisa.
We care, the pandemic is over!